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Enzootic bovine leukosis (EBL) is characterized by 
the development of tumors of lymphatic tissues (lym­
phosarcoma), such as the thymus, spleen and lymph 
nodes. These specialized organs are an integral compo­
nent of the defense system that protects the animal 
against infection, producing antibodies and specialized 
cells which attack bacteria or viruses. Lymphoid cells 
are also found in other organ systems and circulating 
in the blood. Tumors may be found throughout the 
body; clinical signs of EBL depend upon their location. 
Enlargement of the external or superficial lymph nodes 
is common, but internal nodes may also be enlarged in 
the absence of external involvement. 
Tumors often invade the gastrointestinal tract, 
particularly the abomasum. Ulcers or GI obstructions 
may result from abomasal tumors, leading to reduced 
feed intake, weight loss and poor milk production. 
Tumors in the spinal cord may give rise to incoordi­
nation, reduced muscle strength and potentially 
"down" cows. Signs of heart failure may result from 
tumors invading heart muscle. Retrobulbar tumors, 
masses behind the eye but within the orbit, occur fre­
quently and cause the eye to protrude. The develop­
ment of lymphosarcoma is a result of infection by 
bovine leukemia virus (BLV). 
What is BLV? 
Bovine leukemia virus can be identified in many 
cattle herds throughout the United States. Several 
surveys conducted in the past 15 years found that 10 
to 42 percent of dairy animals and 1 to 6 percent of 
beef animals were infected with BLV The percentage 
of infected cattle within herds ranged from 0 to more 
than 50 percent for dairy and from 0 to 20 percent for 
beef. The percentage of herds infected with BLV 
varies from state to state. 
Bovine leukemia virus targets lymphatic tissues. 
Lymphocytes make up one of the classes of white 
blood cells. The virus is incorporated into the make­
up of infected lymphocytes; therefore when these 
cells divide, the presence of the virus is maintained. 
Less than 1 percent of BLV-infected cattle will 
develop lymphosarcoma. Approximately one third of 
cattle with BLV infection develop persistent lympho­
cytosis, an increase in the number of lymphocytes in 
circulation lasting from months to years. Animals 
with lymphocytosis and most animals that become 
infected with BLV do not develop clinical illness. In 
these animals, milk production and fertility are not 
adversely affected. 
Whether or not EBL results from BLV infection, 
this virus is maintained in lymphocytes for the life of 
an infected animal. Antibodies against the virus are 
produced in response to the presence of the virus. 
When antibodies are identified in serum samples 
from cattle exposed to a disease agent, they are classi­
fied as seropositive. In the case of BLV, the virus is 
never eliminated; therefore seropositive cattle are a 
potential source of infection to susceptible animals 
within the herd. 
How is BLV transmitted? 
Because BLV is found in lymphocytes and rarely 
as free virus, exchange of infected cells to a suscepti­
ble animal is required. Three common routes are the 
transfer of blood, consumption of colostrum or milk 
and transfer across the placenta during pregnancy. 
Management procedures that contribute to the 
transfer of infected blood include multiple vaccina­
tions or collection of several blood samples with the 
same needle and syringe, dehorning with a gouge 
or sawing technique, tattooing, or using blood-con­
taminated surgical equipment. Susceptible animals 
may also be exposed if an infected herd-mate has a 
bleeding or weeping wound, whether from injury 
or surgery. 
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Table 1. Guidelines for on-farm control of BLV. 
1. Use individual sterile needles for transdermal injection or blood collection. 
2. Disinfect tattoo equipment between animals. 
3. Use electric dehorners, or disinfect dehorning equipment between animals. 
4. Replace examination gloves and sleeves between animals. 
5. Use milk replacer to feed preweaned calves. 
6. Heat-treat or pasteurize colostrum. 
7. Use BLV-seronegative recipients for embryo transfer. 
8. Wash and rinse instruments in warm water, then submerge in an appropriate disinfectant. 
Rectal palpation has been implicated in the 
transmission of BLY. However, under normal herd 
conditions the use of common palpation sleeves 
failed to increase the incidence of seropositive cows 
when compared to non-palpated, seronegative herd­
mates. Biting flies (horse flies, deer flies) have also 
been studied as a possible source of transfer. The 
results of these studies are not conclusive, but inten­
sifying fly control practices may reduce the risk of 
spreading BLY. 
Seropositive cows secrete BLV antibodies into 
colostrum. Non-infected calves nursing these cows 
will acquire detectable antibody levels in their 
blood. The BLV-antibody levels in these calves 
should decline during the first six to eight months of 
life. Therefore, calves less than six months of age 
from seropositive cows are not routinely tested, 
because the presence of antibodies does not indicate 
infection. Milk from seropositive cows contains 
virus-infected lymphocytes. However, calves that 
have received BLV antibodies in colostrum are usu­
ally protected from milk-borne infection. 
Pasteurizing heavily infected milk to be fed to calves 
less than three days of age will lessen the risk of 
transferring infection. The temperature required for 
inactivating the virus is 60Q C for 30 seconds. 
The mechanism is not fully understood, but it is 
possible for BLV to cross the placenta and infect the 
fetus. Four to 8 percent of calves born to BLV-positive 
cows may be infected during pregnancy. These calves 
can be identified because they will have circulating 
antibodies to BLV prior to receiving colostrum. 
What does BLV cost the producer? 
Direct costs associated with BLV infections are 
most often a result of clinical illness from EBL. Costs 
include: loss of milk production, loss of carcass 
value because affected cows with tumors are con­
demned at slaughter, and loss of the calf if the cow 
was pregnant. Veterinary expenses will be for diag­
nosis only because the disease is not treatable. 
Seropositive, non-symptomatic cattle do not con­
tribute to direct losses because production generally 
is not affected in these animals. 
Indirect losses from BLV infection are associated 
with lost or limited sales of breeder stock, embryos or 
semen to interstate or international markets. Many 
countries have restricted the entry of infected cattle 
and/or their products. Although seronegative recipi­
ents and their calves fail to develop BLV infection 
when embryos from seropositive cows are transferred 
and processed, semen from commercial bull studs 
does not increase the risk of infection to either the calf 
or inseminated cow. There is a growing concern that 
foreign countries may require that the herd of origin 
or bull stud be free of BLV infection. The market 
value of BLV-seropositive cattle may be reduced if 
more producers participate in voluntary control or 
eradication programs that require seronegative 
replacement animals. 
How can BLV be controlled? 
Several methods for controlling the spread of BLV 
within a herd have been investigated: serologic test­
ing of all animals greater than six to eight months of 
age for BLV antibodies and removal of positive ani­
mals from the herd, segregation of cattle into seropos­
itive and seronegative herds, and strict management 
practices that will effectively reduce transmission to 
susceptible animals. Individual herd goals, number 
and age of seropositive animals, and available facili­
ties will determine the most feasible management 
design to implement. 
Smaller herds or herds with few infected ani­
mals may benefit by testing and removing seroposi­
tive animals from the herd. Those removed should 
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be replaced with seronegative animals. Periodic test­
ing will identify additional animals that become 
seropositive. Test and removal may not be feasible 
for larger herds or herds with a large percentage of 
infected animals. The removal of genetically superi­
or cattle may be undesirable, especially from herds 
that provide breeder stock, semen and embryos. 
However, those herds participating in foreign mar­
kets or providing bulls to artificial insemination 
organizations may have an economic incentive to 
consider a BLV control program. 
Alternatively, test-positive animals may be 
retained but segregated from seronegative animals. 
In essence, two herds are created and should be 
managed independently. The infected herd may con­
tinue as a commercial operation and the BLV-free 
herd would then become the source for marketable 
seedstock. The BLV-negative herd should be tested 
on a regular basis and any newly identified seropos­
itive animal should be moved. Movement of cows 
between herds should only occur in one direction, 
from negative to positive. Problems associated with 
a segregation program include the need to duplicate 
housing and feeding facilities and increased man­
agement responsibilities. 
Segregating BLV-infected cattle from non-infected 
cattle may not be feasible in most commercial man­
agement systems. A third alternative for controlling 
BLV transmission is to leave the animal populations 
intact and initiate management procedures to prevent 
transmission. These are listed in Table 1. 
If BLV transmission is prevented, the prevalence 
of BLV in herds will decrease as infected animals are 
culled for other reasons and replaced by seronega­
tive animals. The major advantages of this type of 
control program are that facilities do not have to be 
duplicated and genetically superior individuals are 
not lost to culling as a result of BLV status. 
A major disadvantage is the length of time 
required to observe favorable results or a drop in 
the prevalence of BLV-infected animals. Manage­
ment costs may increase due to additional labor 
required to implement operational changes and the 
use of individual disposable needles and obstetric 
sleeves, disinfection of tattoo equipment and heat 
treatment of colostrum. 
A few states have developed voluntary programs 
for the control of BLY. The programs are designed to 
eradicate BLV infections in the herd and to certify the 
herd as BLV-free. Programs may vary, but essentially 
all animals six months of age or older are tested to 
determine the prevalence of BLV-infected animals so 
that a plan can be developed to eradicate the infection 
from the herd. Some states require removal or segre­
gation of infected cattle from non-infected cattle. In 
such cases, the whole herd is tested every six months 
until the entire herd tests negative. Three consecutive 
negative herd tests at 60- to 90-dayintervals are then 
required for the herd to be certified as BLV-free. The 
herd must be recertified annually by a repeated nega­
tive test of the entire herd. At present, Missouri does 
not have a statewide control program, but testing is 
available through the state veterinary laboratory. The 
costs of blood collection and laboratory testing are the 
responsibility of the herd owner. 
Other requirements of voluntary control pro­
grams include using individual disposable needles 
for all injections or testing procedures, disinfecting 
equipment between animals, and using individual 
obstetric sleeves. Feeding colostrum from BLV­
seronegative dams and feeding pasteurized milk or 
milk replacer is encouraged, in addition to testing 
calves from BLV-seronegative dams as early as two 
months of age. 
Conclusion 
The development of programs for the control of 
BLVon commercial dairy operations is based on iden­
tifying infected and non-infected animals through 
serologic testing and selecting an economical strategy 
to interrupt virus transmission. Decreases in the herd 
prevalence of BLV infection can be accomplished using 
practical and economically sound control procedures. 
This publication was adapted from Pelzer, K. D. and 
Sprecher, D. J. (1993), Controlling BLV infection on dairy 
operations. Veterinary Medicine 88:275-281. 
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